Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Global stocks advance on coronavirus treatment hopes, dollar gains

Mon, 24th Aug 2020 21:12

(Adds close of U.S. markets)

* S&P 500, Nasdaq set all-time peaks

* Apple shares cross $500, Alibaba at record high

* Dollar gains on optimism over COVID-19 treatments

* Gulf of Mexico storms lift crude oil futures

* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

By Herbert Lash

NEW YORK, Aug 24 (Reuters) - A gauge of global equity
markets raced toward a record high on Monday in a rally that
lifted the S&P 500 and Nasdaq to all-time peaks and buoyed the
dollar as hopes for coronavirus treatments bolstered risk
appetite.

U.S. regulators on Sunday authorized the use of blood plasma
from recovered COVID-19 patients as a treatment option. Shares
of AstraZeneca rose on a Financial Times report that the U.S.
government was considering fast-tracking its experimental
vaccine.

The U.S. Food and Drug Administration's move to give
emergency authorization for the use of anti-body rich plasma was
hailed by President Donald Trump. It came a day after he accused
the FDA of impeding the roll-out of treatments until after the
Nov. 3 presidential election.

The World Health Organization was cautious about endorsing
the use of the plasma to treat those who are ill, saying
evidence that it works remains "low quality."

The announcement came on the eve of the Republican National
Convention. Trump on Monday received enough votes to formally
win the nomination as the Republican candidate for the
presidency for another four years.

Progress in treatments or an effective vaccine to gain
control of the virus would aid Trump's re-election chances.

Craig Erlam, senior market analyst at OANDA in London, said
that while it was a highly political move on Trump's part,
"everyone wants to be the first to market, everyone wants to get
the economy back on track and slow down the death rate."

"When you add it all up, it's positive COVID news for the
market," he said.

Equity markets worldwide rose on the vaccine hopes. Europe's
broad FTSEurofirst 300 index closed up 1.62% at
1,439.54, while MSCI's all-country world index
rose 1.06% to 577.02 after overnight gains in Asia.

The benchmark for global equity markets is less than 1%
from scaling its all-time peak reached in February.

AstraZeneca rose 2.1%, providing the FTSE 100
index in London its biggest boost.

Shares of Apple Inc rose 1.3% to cross $500 for the
first time, while Chinese retailer Alibaba's U.S.-listed shares
climbed 3.8%, to a record high. Shares of electric
carmaker also set a new high before retreating 1.8%.

On Wall Street, the Dow Jones Industrial Average rose
1.35%, the S&P 500 gained 1.00%, and the Nasdaq Composite
added 0.6%.

The dollar edged higher, holding above two-year lows against
the euro, as its sell-off against the single currency paused
after the U.S. currency got a boost on Friday. Data showed a
recovery in U.S. business conditions, while European data showed
slowing improvement.

Federal Reserve Chairman Jerome Powell this week will give a
highly anticipated speech about the U.S. central bank's policy
framework review at the Fed's annual Jackson Hole symposium.

The speech will be watched for clues about interest rates
and will likely be the next major dollar driver, with investors
watching to see if Powell signals that the Fed will shift its
inflation target to an average.

The 10-year U.S. Treasury note rose 1.4 basis
points to 0.6542%.

The dollar index rose 0.113%, with the euro
down 0.05% to $1.1789.

The Japanese yen weakened 0.12% versus the greenback
at 105.96 per dollar.

Oil prices strengthened as storms threatening the Gulf of
Mexico shut more than half of the U.S. region's oil production
and on expectations of progress in the development of a COVID-19
treatment.

Brent crude futures settled up 78 cents at $45.13 a
barrel. U.S. crude futures rose 28 cents to settle at
$42.62 a barrel.

Gold prices fell as optimism over the FDA's authorization of
a COVID-19 treatment lifted Wall Street stocks to record highs.
U.S. gold futures settled down 0.4% at $1,939.20 an
ounce.

(Reporting by Herbert Lash; Editing by Dan Grebler and Leslie
Adler)

More News
16 Apr 2024 08:39

AstraZeneca's hails Imfinzi survival data on cancer form

(Alliance News) - AstraZeneca PLC on Tuesday said that its immunotherapy Imfinzi showed positive survival rate in people with advanced biliary tract cancer.

Read more
12 Apr 2024 12:55

EU regulator rules out link between weight-loss drugs and suicidal thoughts

April 12 (Reuters) - The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts, it said on Friday, ending a nine-month probe.

Read more
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.